xT CDx
Tempus AI, Inc. · Decision date Sep 2, 2026
What did the FDA approve?
Supplement S002 to PMA P210011 covers a pre-specified change control plan (PCCP) that would modify use of the device from a single laboratory to multiple laboratories. The listed supplement reason is change in design, components, specifications or material, on the normal 180-day track. The device category is a next generation sequencing oncology panel, somatic or germline variant detection system, in pathology under product code PQP, filed by Tempus AI, Inc.
The source field states approval of the PCCP for that scope change, but does not identify the components or specifications altered, the number or identity of additional laboratories, or supporting data. The statement's purpose is not independent evidence of analytical or clinical performance, and it does not extend the original PMA to new indications.
FDA approval order statement
Approval for a Pre-specified Change Control Plan (PCCP) to modify the use of the device at a single laboratory to multiple laboratories
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Pathology
- Decision date
- Sep 2, 2026
- FDA change category
- Change Design/Components/Specifications/Material
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210011/S002
- Regulatory pathway
- PMA supplement
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Sep 2, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Tempus AI, Inc.
- Product code
- PQP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210011. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210011 · Original PMA
xT CDx
P210011/S002 received
Application receipt date recorded by FDA.
P210011/S002 · FDA decision
Normal 180 Day Track
Timeline entries are records held by MedtechLedger for P210011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
xT CDxP210011 | Tempus AI, Inc. | PMA approval | Apr 28, 2023 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
FoundationOne CDxP170019/S069 | Foundation Medicine, Inc. | PMA supplement | Sep 16, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tempus AI, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 600 W Chicago Ave., Suite #510, Chicago, IL, 60654
Sources and methodology
- Original FDA record: P210011/S002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




